We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-6.17%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$352M
AUM Growth
-$60.2M
Cap. Flow
+$19M
Cap. Flow %
5.38%
Top 10 Hldgs %
95.16%
Holding
20
New
–
Increased
3
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$12.5M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.75M
3
SLNO
Soleno Therapeutics
SLNO
+$2.66M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$101M 28.51%
4,168,718
– –
VERA icon
2
Vera Therapeutics
VERA
$2.3B
$69.3M 19.66%
2,960,231
– –
ACET icon
3
Adicet Bio
ACET
$85.2M
$42.2M 11.96%
132,212
– –
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$42.1M 11.95%
1,314,012
+437,356
+50% +$12.5M
JSPR icon
5
Jasper Therapeutics
JSPR
$21M
$19.5M 5.54%
562,856
– –
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$708M
$19.5M 5.53%
1,435,106
+231,971
+19% +$3.75M
EFTR
7
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$18.9M 5.36%
192,885
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
$12.1M 3.44%
2,457,499
– –
OKUR
9
OnKure Therapeutics
OKUR
$154M
$6.08M 1.72%
207,396
– –
SIEN
10
DELISTED
Sientra, Inc.
SIEN
$5.19M 1.47%
234,983
– –
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$3.96M 1.12%
1,201,507
+514,667
+75% +$2.66M
NCNA
12
NuCana
NCNA
$5.49M
$3.28M 0.93%
667
– –
PRTK
13
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.08M 0.87%
1,041,131
– –
XCUR icon
14
Exicure
XCUR
$10.2M
$1.37M 0.39%
46,513
– –
MTEM
15
DELISTED
Molecular Templates, Inc.
MTEM
$690K 0.2%
13,333
– –
SYRE icon
16
Spyre Therapeutics
SYRE
$8.54B
$553K 0.16%
9,620
– –
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$406K 0.12%
131,036
– –
OBSV
18
DELISTED
ObsEva SA Ordinary Shares
OBSV
$133K 0.04%
87,999
– –
OCGN icon
19
Ocugen
OCGN
$416M
$23K 0.01%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2022 Portfolio in Review

As of Q1 2022, Abingworth held 20 positions worth $352M, down 15% from $413M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Abingworth deployed $19M of net new capital in Q1 2022, adding to 3 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

  • Abingworth added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $12.5M increase.
  • Abingworth's ten largest holdings make up 95% of its $352M portfolio in Q1 2022.
  • Abingworth opened 0 new positions and closed 0 in Q1 2022.
  • Abingworth's portfolio value fell 15% quarter-over-quarter to $352M.

Based on Abingworth's 13F filing for Q1 2022, filed 16 May 2022.